Table 1. Panel of Protein Targets for Screening.
proteina | MWb | hitsc | nonpromiscuous hitsd | catalytic Cyse | Cys residuesf | possible therapeutic indicationsg |
---|---|---|---|---|---|---|
QSOX1 | 58084 | 0/993 | 0 | noh | 12 | cancer53,54 |
PCAF | 19452 | 0/993 | 0 | no | 3 | HIV,55 cancer56,57 |
PBPR504C | 57903 | 2/983 | 2 | no | 1 | antibiotic resistance58 |
K-RasG12C | 19245 | 10/968 | 7 | no | 3 | cancer37,59 |
USP8 | 44429 | 20/923 | 7 | yes | 12 | cancer,60 Cushing’s disease61 |
NNMT | 31248 | 30/299 | 22 | no | 8 | cancer,62 diet-induced obesity63 |
OTUB2 | 27312 | 47/938 | 42 | yes | 4 | viral infection,64 diabetes,65 ALS66 |
NUDT7 | 26672 | 36/973 | 24 | yes | 4 | diabetes67 |
NV3CP | 19284 | 10/824 | 9 | yes | 5 | viral infection68 |
BSA | 66464 | 0/981 | 0 | no | 23 | negative control |
Acronyms are as follows: quiescin sulfhydryl oxidase 1 (QSOX1); penicillin-binding protein 3 (PBP); ubiquitin-specific peptidase 8 (USP8); nicotinamide N-methyltransferase (NNMT); norovirus 3C protease (NV3CP); bovine serum albumin (BSA).
Molecular weight of construct in Da.
Number of fragments with >50% labeling/compounds for which labeling could be evaluated.
Number of hits that did not label any other protein to >50%.
Indicates whether a catalytic cysteine is present in the protein.
Number of cysteine residues in protein.
Indicates possible therapeutic rationale to inhibit this target.
QSOX1 contains a catalytic disulfide.